Fate Therapeutics, Inc. (FATE) — Analyst outlook / Analyst consensus target is. Based on 31 analyst ratings, the consensus is bullish — 16 Buy, 13 Hold, 2 Sell.
The consensus price target is $39.50 (low: $3.00, high: $145.00), representing an upside of 2847.8% from the current price $1.34.
Analysts estimate Earnings Per Share (EPS) of $-1.62 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.64 vs est $-1.62 (missed -1.3%). 2025: actual $-1.15 vs est $-1.15 (missed -0.4%). Analyst accuracy: 99%.
FATE Stock — 12-Month Price Forecast
$39.50
▲ +2,847.76% Upside
Average Price Target
Based on 31 Wall Street analysts offering 12-month price targets for Fate Therapeutics, Inc., the average price target is $39.50, with a high forecast of $145.00, and a low forecast of $3.00.
The average price target represents a +2,847.76% change from the last price of $1.34.
Highest Price Target
$145.00
Average Price Target
$39.50
Lowest Price Target
$3.00
FATE Analyst Ratings
Buy
Based on 31 analysts giving stock ratings to Fate Therapeutics, Inc. in the past 3 months
EPS Estimates — FATE
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.64
vs Est –$1.62
▼ 1.3% off
2025
Actual –$1.15
vs Est –$1.15
▼ 0.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — FATE
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.014B
vs Est $0.013B
▲ 2.4% off
2025
Actual $0.007B
vs Est $0.007B
▲ 0.4% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
